Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Suzetrigine

A non-opioid painkiller that selectively blocks the NaV1.8 sodium channel, approved in the United States in January 2025 for moderate to severe acute pain in adults, the first of a new class. This family brings together the active ingredient, labelled standards and other impurities.

Did you know?The NaV1.8 channel is found mainly in the peripheral neurons that sense pain, not in the brain: the medicine stops the signal before it reaches the central nervous system.

SuzetrigineGo to the active ingredient →
SuzetrigineActive ingredientSuzetrigineCat. No. P-S142-001CAS 2649467-58-1

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.